| 1 |
How might using gold nanoparticles in electrochemical sensors enhance early-stage disease detection?
|
2. By increasing surface interactions for more accurate biomarker capture |
|
Gold nanoparticleshave a large surface area which increases the chances of dna or proteins will bind to the sensor surfacewhich eill lead to improvements on biomarker detection accuracy and can help detect diseases at an early stages. |
i found it on section 3.2 key nanomaterial sued in electrochemical sensors. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following best explains how label-free electrochemical sensors support point-of-care medical diagnostics?
|
3. They provide direct measurement of target molecules with minimal preparation |
|
label free sensors detect biomolecular interactions withour enzumes or fluorescent marjers which simplifies the process reduces time and is also real time |
i found it from section 2 fudamentals of electrochemical sensors |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
Why is electrochemical transduction considered advantageous over optical transduction in medical diagnostic sensors?
|
2. It is more compatible with smartphone integration for remote analysis |
|
Electrochemical transduction produces electrical signals that can be easily processed by small electronic devices it allows to be used at home or remote use. |
around section 4 integratino of nanotechnology with electrochemical senosrs |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which action would most effectively increase specificity in a sensor designed to detect a single disease biomarker?
|
3. Functionalizing the electrode with disease-specific aptamers |
|
Aptamers are short DNA or RNA sequences that bind to biomarkers specificallyby addign it to sensor durfaces it enhaces specificity ensuring that only the target molecule is detected reducing false detection. |
i found it in section 3 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
In a scenario where a sensor must detect ultra-low concentrations of a cancer biomarker, which modification is most critical?
|
3. Incorporating nanostructures to increase surface-to-volume ratio |
|
Nanostructures increase the number of binding sites available allowing ti to be esaier to detect veru low concentration of biomarker surface area to volume ration is a key principle in increasing sensitivity |
i got it in the sensitivity part 6.1.1 and surface area to volume ratio. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
Why might two electrochemical sensors using the same nanomaterial produce inconsistent results?
|
3. Variations in nanomaterial synthesis affect structural uniformity |
|
WHen using the samt type of nanmaterial there are still small inconsistencies like their sizr and sha[e which can lead to differences in sensor performance making uniofomaity and standardization difficult. |
4.3.1. Teachnnical and materail challenges |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
Which characteristic makes nanotechnology-based electrochemical sensors especially suitable for wearable medical devices?
|
3. They allow miniaturization without losing sensitivity |
|
Nanotechnology allows very samll sensors that still contain high sensitivity which makes them ideal for using with earable devices that need to be reliable and firm |
i found it of the wearble senosrs part 4.3 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What would likely happen if the bioreceptor layer is poorly immobilized on the sensor surface?
|
3. Target biomolecules may not bind effectively, leading to weak or inaccurate signals |
|
Poor immoblizeation of bioreceoter layer causes unstable or weak binfing with biomarkere swhich leads difrectly to impactinf the streangth adn accuracy of the output signal. |
i faptamers is not well immobilized it can't properly bind to the target molecules which leads to harmful results |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
Which modification would most directly enhance electron transfer in the sensor system?
|
2. Incorporating carbon nanotubes on the electrode surface |
|
CaRBON Nnotubes improve the conductivity and surface area of electrodes afacilitiating faster and a more efficient ectron transer during sensing. |
i founs it on section 3.2 ket nanomaterails in electrochemical sensors |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
How can digital sensing technologies best support personalized cancer care?
|
2. By collecting real-time data on patient-specific symptoms and responses |
|
using real time infividusl data gives healthcare professionals individualized data that allows them to make treatments to each pateitnt improving effectiveness and reduing uncesseary compolicationsl. |
figital sensing prioritizes individuals and these indignts helps soctors personalize treatment making it more responsive and precise |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
If a clinician needs to monitor fatigue and motion in cancer patients at home, which device should be prioritized?
|
2. Smart accelerometers in wearables |
|
Accelerometers are used in wearable devices to monitor motion and physical activity. For cancer patients, they are effective tools for tracking fatigue and movement patterns at home. whihc allows for a precise tracking. |
This question focuses on tracking fatigue or motionwhich are physical activity indicatiors Devices like accelerometers are often used in wearables, devices and are designed to detect movement patterns and levels of activity. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Why is combining sensor data with patient-reported outcomes (PROs) important in digital cancer care?
|
3. It allows a holistic understanding of patient experience |
|
Sensor data gives many objective views while PROs give subjective views like pain. so by comningng it together it gives a better view of the patient's condition. |
i found it on the part where they mentioned about the roles of patient report outcomes |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
A hospital invested in wearable digital monitoring but received low engagement from patients. Which of the following is most likely a contributing factor?
|
3. Low digital health literacy among patients |
|
Even with good infrastructure if patients are not confident using digital health tools to mointor the engagement will be low and educaiton like literacy is important and support also are essential for successful adoption. |
i found it on the challenges of impolementation part |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
Which future trend is most aligned with the development of emerging digital cancer platforms?
|
2. Creation of pocket-sized biosensing tools integrated with smartphones |
|
The article discussesd development of miniaturized and portable biosensors that link to smartphones for fast diagnosis |
7.4 talks about fture plans of digital sesning |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How can real-time symptom monitoring positively affect treatment decisions?
|
3. By enabling rapid intervention before major deterioration |
|
real time monitoring continuoisly allows healthcare peoples to act quickly when early signs appear allowing them to improve outcomes and precent or avoid complications. |
i found it in the abstract part |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which technology is best suited to detect rare cancer biomarkers with high precision?
|
1. Digital ELISA |
|
Digital ELISA is reaaly sensitive and it can detect rare biomarkers at very low concentrations making it very suitable for cancer dianosis with high precision. |
i found in on the poc applications part |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
Why is collaboration between data scientists and clinicians essential in digital oncology platforms?
|
3. Data insights require clinical validation for real-world use |
|
Clinicians must evaluate these inforamtion and together the data can be interpreted correctly and translated into patient care, which is why collaboration is essential. |
i founs it on the part where they mentioned about stakeholder collaboration. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
Which outcome is most likely when cancer patients actively use digital health tools to track their condition?
|
2. They engage more actively in shared treatment decisions |
|
When patients track their condition digitally, they gainmore knowlefge about their health, which influneces them to participate more in care treatments. |
i found it on the part where it talks aobbut patient outcomes and evualtion and engagement. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
A research team is developing a highly selective electrochemical sensor for detecting cancer biomarkers in blood. Based on the diagram, which combination of nanoparticle properties would most likely enhance both specificity and signal sensitivity?
|
2. Small spherical particles with antibody-conjugated targeting ligands |
|
small sizes increases surfcae aresa, targeting ligansa imporve specificity and combines togehter it will enhacnce or imporove accuracy and sensitiivoty of signal. |
I found it in figure 6 the basic features of nanoparticles and used the properties of nanomaterials in part 3.12 to helpp me analyzse the information. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
A hospital is planning to adopt a single digital sensing platform to support a wide range of diagnostic applications. Based on the image, which of the following most justifies this decision?
|
2. One platform can be customized to detect toxins, cancer biomarkers, and heavy metals using interchangeable biorecognition elements |
|
ONe platform can be used to detect tovicns and cacner biomarkers becasue sensor platforms can detect many elements like antobody and used to detect many targets with one device. |
I found it on figure 4 the representation of diagnostic and analytical application of LOC device in biosensing. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|